Arxiv Universal PublishingsSGLT2 INHIBITORS BEYOND DIABETES A RETROSPECTIVE AUDIT OF PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTIONMehakNazeemauthorHaleema IqbalauthorNayabNisarauthorSaifullahauthorHeart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes. 2026-05-10Research Science and Innovation HouseMaqola

For work being deposited by its own author: In self-archiving this collection of files and associated bibliographic metadata, I grant Arxiv Universal Publishings the right to store them and to make them permanently available publicly for free on-line. I declare that this material is my own intellectual property and I understand that Arxiv Universal Publishings does not assume any responsibility if there is any breach of copyright in distributing these files or metadata. (All authors are urged to prominently assert their copyright on the title page of their work.)

For work being deposited by someone other than its author: I hereby declare that the collection of files and associated bibliographic metadata that I am archiving at Arxiv Universal Publishings is in the public domain. If this is not the case, I accept full responsibility for any breach of copyright that distributing these files or metadata may entail.

Clicking on the Deposit Item Now button indicates your agreement to these terms.